Latest Conference Articles

Patients with allergic asthma could often have no clinical history of atopic dermatitis.

Most cases had onset after 4 hours and were mild, which Dr. Anvari noted should not contraindicate future COVID-19 vaccine doses.

To date, dupilumab is the only biologic medicine to show positive, clinically meaningful phase 3 results in adults and adolescents with EoE.

Knowledge on distinguishing moderate and severe eczema increased the most after the video training.

Investigators from the Cincinnati Children’s Hospital Medical Center tested a new allergic reaction severity grading system.

Dr. McKeon speaks of how patients can be more involved with managing their asthma and allergies by avoiding exposures in their own homes.

The most common burden of disease were itching, dry or rough skin, and cracked skin.

Those who were breastfed for less than 4 months also had lower risks of developing atopic diseases.

Though telemedicine has improved upon school-based asthma programs across the country, Dr. Phipatanakul notes that the adoption of these programs can be difficult to implement.

Urticaria and angioedema with oral mucocutaneous involvement were commonly labeled as anaphylaxis upon presentation.

Dr. Trivedi speaks of a new text-based program that helps provide asthma care to children from communities of color, as well as how COVID-19 affected school-based asthma programs.

The proportion of anaphylaxis episodes was higher in the cohort of patients with peanut allergies, compared to a control group of patients with non-peanut food allergies.

Dr. Zein speaks of the relationship between eosinophil count and COVID-19 illness and mortality, especially as it related to inhaled corticosteroid use.

The enrollment distribution was consistent by ethnicity over the course of 18 years, with no change in diversity over time despite there being an increase in the UK in the minority population.

Of the SCD patients who contracted COVID-19, 49% of them visited the Grady Comprehensive Sickle Cell center because of a vaso-occlusive event.

Data show patients with sickle cell disease identified by distinct cognitive profile should have neurorehabilitation tailored to each unique profile.

After 2 months of voxelotor treatment, all patients with sickle cell anemia perceived global improvement, but peak VO2 did not change in 8 of 9 patients.

Data show most patients (60.3%) with sickle cell disease achieved a Hb increase of >1 g/dL during the follow-up period.

Patients with SCD were not at an increased risk of death or disease complications.

High dose vitamin D supplementation has been linked to fewer pain days and higher physical activity scores for patients with chronic pain.

New ASH 2021 data for the stem cell transplant therapy suggest it has a durable and safe benefit for adults with severe disease.

Investigators added improvements were needed regarding access to complete diagnostic evaluation among Black patients, citing disparities in care.

New research on the preclinical product TALGlobin01 reveals the potential impact that gene therapy can have on the future of sickle cell disease treatment.

New cohort analysis suggest a heightened risk of atrial fibrillation may be worsening patients' life expectancies.

Investigators aimed to improve lentiviral vectors to boost therapeutic β-like globin levels without increasing the mutagenic vector load in hematopoietic stem/progenitor cells.

New data for the Rocket Pharmaceutical gene therapy candidate show durable benefit in patients 6 months out from transplant.

The global biopharmaceutical company released research data on rozanolixizumab and zilucoplan at the 2021 ASH annual meeting and exposition.

An international assessment shows many patients are wary of emergency rooms, and clinicians want more diverse therapies.